Brisk trade in risky three-drug 'bet' option after BMS/Celge...

Bristol-Myers Squibb’s $74 billion merger with Celgene went ahead this week after clearance from US competition regulators, and the focus has shifted on to whether Celgene shareholders will

Mavenclad helps Merck shrug off Rebif decline in MS

NICE backs NHS funding for two cannabis-based drugs for firs...

NICE has recommended two of GW Pharma's cannabis-based medicines, the first time that medicines derived from the plant have been recommended for NHS funding.

Sanofi settles dispute with Genzyme investors over MS drug

Sanofi has settled a long-running dispute with shareholders in the biotech Genzyme, who claimed the big pharma deliberately held back development of a multiple sclerosis drug to avoid payme

Biogen bags FDA okay for Tecfidera follow-up Vumerity

Getting MS diagnosis right

MS advocate Trishna Bharadia explains how diagnosis needs to change and why pharma shouldn’t be using the word ‘patient’.